- Home
- ACAD vs EQX Comparison
ACAD vs EQX Comparison
Compare ACAD & EQX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- EQX
- Stock Information
- Founded
- ACAD 1993
- EQX 2007
- Country
- ACAD United States
- EQX Canada
- Employees
- ACAD N/A
- EQX N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- EQX Precious Metals
- Sector
- ACAD Health Care
- EQX Basic Materials
- Exchange
- ACAD Nasdaq
- EQX Nasdaq
- Market Cap
- ACAD 2.5B
- EQX 2.8B
- IPO Year
- ACAD 2004
- EQX N/A
- Fundamental
- Price
- ACAD $21.57
- EQX $6.65
- Analyst Decision
- ACAD Buy
- EQX
- Analyst Count
- ACAD 14
- EQX 0
- Target Price
- ACAD $27.08
- EQX N/A
- AVG Volume (30 Days)
- ACAD 3.0M
- EQX 12.2M
- Earning Date
- ACAD 05-07-2025
- EQX 05-07-2025
- Dividend Yield
- ACAD N/A
- EQX N/A
- EPS Growth
- ACAD N/A
- EQX N/A
- EPS
- ACAD 1.37
- EQX 0.64
- Revenue
- ACAD $996,283,000.00
- EQX $1,696,526,000.00
- Revenue This Year
- ACAD $13.49
- EQX $40.61
- Revenue Next Year
- ACAD $10.58
- EQX $14.56
- P/E Ratio
- ACAD $15.76
- EQX $9.85
- Revenue Growth
- ACAD 22.42
- EQX 54.88
- 52 Week Low
- ACAD $13.40
- EQX $4.48
- 52 Week High
- ACAD $25.23
- EQX $7.45
- Technical
- Relative Strength Index (RSI)
- ACAD 68.70
- EQX 53.47
- Support Level
- ACAD $21.95
- EQX $6.54
- Resistance Level
- ACAD $22.62
- EQX $6.85
- Average True Range (ATR)
- ACAD 1.21
- EQX 0.20
- MACD
- ACAD 0.23
- EQX 0.05
- Stochastic Oscillator
- ACAD 56.27
- EQX 79.50
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.